Hormonal
Liraglutide (1.8 mg) improves liver enzymes and reduces hepatic steatosis in MASH patients, though its ability to resolve NASH histology is modest compared to semaglutide.
Liraglutide 1.8 mg can significantly lower liver enzymes (ALT/AST) and reduce liver fat in MASH patients. However, it is less effective than semaglutide at fully resolving the inflammation (NASH) itself, so it may be a good option for enzyme control but less so for complete histological reversal.
In the liraglutide group, 9% of patients achieved resolution of NASH with liraglutide (vs. 9% with placebo, p = .019)... treatment with liraglutide was reported to have resulted in a notable improvement in the liver enzymes aspartate aminotransferase (64 vs. 37 IU/L; p < .05) and ALT (90 vs. 36 IU/L; p < .05).
Why this rating
Based on the LEAN trial (phase 2), which is well-designed but smaller than the semaglutide trials.
Source
The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis
Manal F. Abdelmalek et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15524
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →